Aspirin withdrawal: A risk factor for ischemic stroke severity - 06/07/21
, M. Berrada a, Z. Abdulhakeem a, S. Bellakhdar a, B. El Moutawakil a, b, M. Abdoh Rafai a, cBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 4 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Introduction |
Acetylsalicylic acid (ASA) cessation, is suggestive of a rebound phenomenon laying the ground for ischemic stroke (IS) re-occurrence but nothing is known about its implication for IS severity (ISS). Thus, the aim of our study is to examine whether or not aspirin withdrawal is a risk factor for ISS.
Patients and methods |
This study, recruited patients having presented an IS in the following 2 weeks of ASA withdrawal, matched with treatment free cases. ISS was evaluated in all patients at admission using the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin scale (mRS) at 3 months’ follow-up.
Findings |
Fifty cases were included in this study and fifty, manually matched, controls. ISS analysis found that the case group had a more severe stroke at admission (mean NIHSS: 12.76 (±7.319) in cases vs 10.04 (±5.562) in controls, P=0.039), with ASA discontinuation judged as a risk factor directly related to ISS regardless of the underlying cardiovascular risk factors (using the multivariate analysis).
Conclusion |
Our study's findings suggest that aspirin interruption over a 15-days period could result in a more severe IS in the acute phase. To our knowledge, no study has ever discussed this outcome, shedding the light on the pressing need for larger studies with various withdrawal periods to support these data.
Le texte complet de cet article est disponible en PDF.Keywords : Aspirin withdrawal, Ischemic stroke severity, National Institutes of Health Stroke Scale, Modified Rankin scale
Plan
Vol 46 - N° 4
P. 171-174 - juillet 2021 Retour au numéro
Article précédent
- Systematic screening for a proximal DVT in COVID-19 hospitalized patients: Results of a comparative study
- Y. Fares, Y.C. Sinzogan-Eyoum, P. Billoir, A. Bogaert, G. Armengol, K. Alexandre, J. Lammens, M. Grall, H. Levesque, Y. Benhamou, S. Miranda
- Prevalence and management of antivitamin K overdose in a hospital setting
- A. Zemouri, F. Lin, O. Billuart, E. Sacco, J. Emmerich, P. Priollet, A. Yannoutsos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?